ROCK2-IN-13
ROCK2-IN-13 is a selective ROCK2 inhibitor. ROCK2-IN-13 reduces nuclear expression by disrupting the interaction of ROCK2 with transcriptional co activators p300> and PGC 1α, repressing oncogenic transcription. ROCK2-IN-13 activates FOXO1 driven PTEN expression, leading to suppression of the PI3K/Akt pathway, induction of G2/M cell cycle arrest, and promotion of apoptosis. ROCK2-IN-13 ablates the nuclear transcriptional function of ROCK2 that sustains oncogenic signaling and restores the tumor suppressive PTEN/FOXO1 axis. ROCK2-IN-13 can be used for prostate cancer reseach.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C18H11F3N4S
- Masse moléculaire:372.37
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
[1]|
ROCKII |
FOXO1 |
PI3K |
Akt |
In Vitro
ROCK2-IN-13 (compound 25) (30 μM, 24 h) exhibits strong antiproliferative activity (84.5% inhibition) in human prostate cancer cells (PC-3), demonstrates potent and consistent efficacy with GI50 values of 3.7 μM in PC-3 cells and 3.9 μM in LNCaP cells, and shows substantially lower cytotoxicity toward normal cells (CC50s: 55.0 μM for CCD841 and 41.8 μM for HEK-293)[1].
ROCK2-IN-13 reduces the expression of the highly expressed oncoprotein FOXA2 (HNF-3β) along with the less abundant FOXO1 in PC-3 cells[1].
ROCK2-IN-13 (1-10 μM) induces a concentration-dependent decrease in FOXA2 mRNA and an increase in FOXO1 mRNA, leading to reduced nuclear FOXA2 protein, enhanced FOXO1 nuclear accumulation, decreased cytoplasmic FOXO1 phosphorylation, and ultimately suppressing the PI3K/Akt axis via PTEN upregulation, which subsequently elevates p27 expression and the Bax/Bcl-2 ratio while reducing cyclin D1 levels, in PC-3 and LNCaP cells[1].
ROCK2-IN-13 (1-10 μM, 24 h) reduces the proportions of cells in the G1 and S phases and induces a marked accumulation of cells in the G2/M phase in PC-3 cells[1].
ROCK2-IN-13 (1-10 μM) induces a concentration-dependent induction of apoptosis with the proportion of early and late apoptotic cells reaching 15.7% and 8.7%, respectively, at 10 μM in PC-3 cells[1].
ROCK2-IN-13 (1-10 μM, 48 h) suppresses the PI3K/Akt signaling pathway predominantly via PTEN activation, rather than through direct EGFR inhibition in PC-3 cells[1].
ROCK2-IN-13 (1-10 μM, 48 h) induces a concentration-dependent increase in PGC-1α mRNA, significantly reduces the mRNA expression of both ROCK1 and ROCK2 with a greater effect on ROCK2, decreases nuclear ROCK2 protein while leaving cytoplasmic ROCK1 unchanged, enhances the transcription of FOXO1 by recruiting RNA polymerase II and PGC-1α to its promoter, and facilitates PTEN transcription by promoting the binding of RNA polymerase II and key co-regulators (ROCK1/2, PGC-1α, and p300) to the PTEN promoter in PC-3 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:PC-3 cells
-
Concentration:30 μM
-
Incubation Time:24 h
-
Result:Exhibited the strongt antiproliferative activity achieving inhibition rates exceeding 80%.
-
Cell Line:PC-3 cells
-
Concentration:1, 3, and 10 μM
-
Incubation Time:24 h
-
Result:Reduced the proportions of cells in the G1 and S phases and induced a marked accumulation of cells in the G2/M phase.
-
Cell Line:PC-3 cells
-
Concentration:1, 3, and 10 μM
-
Incubation Time:48 h
-
Result:Exhibited greater cytotoxicity than Gefitinib (HY-50895) (a selective EGFR inhibitor) and their combined treatment synergistically reduced PC-3 cell viability.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:PC-3 cells (1 × 106, s.c.) induce- BALB/c nude mice (Seven-week-old)[1]
-
Dosage:30 and 50 mg/kg
-
Administration:i.p., daily for 26 days
-
Result:Significantly and dose-dependently reduced tumor growth in the xenograft model.
Had anti-tumor effect after 26 days of daily administration at 3 mg/kg.
Produced a significantly lower tumor weight than docetaxel.
Chemical Information
-
Masse moléculaire 372.37
-
Formule C18H11F3N4S
-
SMILES
N#CC1=CC=C(C=C1C(F)(F)F)NC(NC2=CC=C3C=NC=CC3=C2)=S
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)